Satsuma Pharmaceuticals, Inc.

STSACIK 0001692830 · Every Form 4 filed by insiders at this issuer. See financials →

Annual report (10-K)

Latest 10-K/A filed Apr 28, 2023. Sentiment + YoY language diff vs prior year. Read sections →

Signal:NeutralFull-doc fallback

Full filing:tone 0.0001

Sentiment via Loughran-McDonald lexicon · YoY diff via Jaccard similarity + paragraph set difference.

YoY shift: Unscored

Year-over-year tone shift - average net-tone change across Risk Factors and MD&A vs the prior 10-K.

Why YoY instead of absolute: the LM lexicon has ~6.6× more negative words than positive (legal/risk-disclosure language is heavy on hedging), so every 10-K reads bearish on raw tone. Year-over-year change strips that bias and surfaces the actual shift in management's framing.

Per-snippet highlights

Sentence-level sentiment highlighting with category and subcategory filters is coming once the snippet-scoring pipeline lands. For now, dig into the actual section text on the Sections tab.

Top insiders

Most active reporters at Satsuma Pharmaceuticals, Inc.

Name	Roles	Filings
O'Neil Thomas P.	Officer	2
Ra Capital Management, L.P.	Director10% Owner	2
Ra Capital Healthcare Fund LP	Director10% Owner	2
Riebe Michael T	Director	2
Sandoval Elisabeth	Director	2

Showing 6-10 of 15

Per pagePrevPage 2 of 3Next

All filings

23 Form 4 / 4-A filings, newest first

Filed	Insider	Top transaction	Shares	Price	Value
Jun 8, 2023	Kollins John A President and CEO · Director	UTender	305,911	$0.91	$278,379
Jun 8, 2023	Soloway Thomas P Director	Holdings only	-	-	-
Jun 8, 2023	Sandoval Elisabeth Director	Holdings only	-	-	-
Jun 8, 2023	Riebe Michael T Director	Holdings only	-	-	-
Jun 8, 2023	Takanashi Ken Director · 10% Owner	PPurchase	22,053,581	$0.91	$20,068,759

Showing 6-10 of 23

Per pagePrevPage 2 of 5Next

Real-time Form 4 intelligence. Smarter insider tracking.

Filed		Top transaction	Shares	Price	Value

Satsuma Pharmaceuticals, Inc.

Annual report (10-K)

Top insiders

All filings

External resources

Permalink